Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Early P 1 (1)
P 1 (1)
P 2 (1)

Trial Status

Active Not Recruiting2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05407441Phase 1Active Not RecruitingPrimary

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

NCT02114229Phase 2Active Not Recruiting

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

NCT06942039Early Phase 1Recruiting

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Showing all 3 trials

Research Network

Activity Timeline